ID   ERBB2_HUMAN             Reviewed;        1255 AA.
AC   P04626; B2RZG3; B4DHN3; Q14256; Q6LDV1; Q9UMK4;
DT   13-AUG-1987, integrated into UniProtKB/Swiss-Prot.
DT   13-AUG-1987, sequence version 1.
DT   02-NOV-2010, entry version 149.
DE   RecName: Full=Receptor tyrosine-protein kinase erbB-2;
DE            EC=2.7.10.1;
DE   AltName: Full=Metastatic lymph node gene 19 protein;
DE            Short=MLN 19;
DE   AltName: Full=Proto-oncogene Neu;
DE   AltName: Full=Proto-oncogene c-ErbB-2;
DE   AltName: Full=Tyrosine kinase-type cell surface receptor HER2;
DE   AltName: Full=p185erbB2;
DE   AltName: CD_antigen=CD340;
DE   Flags: Precursor;
GN   Name=ERBB2; Synonyms=HER2, MLN19, NEU, NGL;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   MEDLINE=86118663; PubMed=3003577; DOI=10.1038/319230a0;
RA   Yamamoto T., Ikawa S., Akiyama T., Semba K., Nomura N., Miyajima N.,
RA   Saito T., Toyoshima K.;
RT   "Similarity of protein encoded by the human c-erb-B-2 gene to
RT   epidermal growth factor receptor.";
RL   Nature 319:230-234(1986).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORM 1), AND VARIANT
RP   ALA-1170.
RX   MEDLINE=86070181; PubMed=2999974; DOI=10.1126/science.2999974;
RA   Coussens L., Yang-Feng T.L., Liao Y.C., Chen E., Gray A., McGrath J.,
RA   Seeburg P.H., Libermann T.A., Schlessinger J., Francke U.,
RA   Levinson A., Ullrich A.;
RT   "Tyrosine kinase receptor with extensive homology to EGF receptor
RT   shares chromosomal location with neu oncogene.";
RL   Science 230:1132-1139(1985).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS CYS-452; VAL-655 AND
RP   ALA-1170.
RG   NIEHS SNPs program;
RL   Submitted (DEC-2002) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 4).
RC   TISSUE=Brain;
RA   Wakamatsu A., Yamamoto J., Kimura K., Ishii S., Watanabe K.,
RA   Sugiyama A., Murakawa K., Kaida T., Tsuchiya K., Fukuzumi Y.,
RA   Kumagai A., Oishi Y., Yamamoto S., Ono Y., Komori Y., Yamazaki M.,
RA   Kisu Y., Nishikawa T., Sugano S., Nomura N., Isogai T.;
RT   "NEDO human cDNA sequencing project focused on splicing variants.";
RL   Submitted (OCT-2007) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-191 (ISOFORM 1).
RX   MEDLINE=87286898; PubMed=3039351;
RA   Tal M., King C.R., Kraus M.H., Ullrich A., Schlessinger J., Givol D.;
RT   "Human HER2 (neu) promoter: evidence for multiple mechanisms for
RT   transcriptional initiation.";
RL   Mol. Cell. Biol. 7:2597-2601(1987).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 737-1031.
RX   MEDLINE=86016729; PubMed=2995967; DOI=10.1073/pnas.82.19.6497;
RA   Semba K., Kamata N., Toyoshima K., Yamamoto T.;
RT   "A v-erbB-related protooncogene, c-erbB-2, is distinct from the c-
RT   erbB-1/epidermal growth factor-receptor gene and is amplified in a
RT   human salivary gland adenocarcinoma.";
RL   Proc. Natl. Acad. Sci. U.S.A. 82:6497-6501(1985).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 832-909.
RC   TISSUE=Mammary carcinoma;
RX   MEDLINE=85272597; PubMed=2992089; DOI=10.1126/science.2992089;
RA   King C.R., Kraus M.H., Aaronson S.A.;
RT   "Amplification of a novel v-erbB-related gene in a human mammary
RT   carcinoma.";
RL   Science 229:974-976(1985).
RN   [10]
RP   NUCLEOTIDE SEQUENCE OF 1081-1245, AND VARIANT ALA-1170.
RX   MEDLINE=94000386; PubMed=8104414; DOI=10.1089/dna.1993.12.611;
RA   Sarkar F.H., Ball D.E., Li Y.W., Crissman J.D.;
RT   "Molecular cloning and sequencing of an intron of Her-2/neu (ERBB2)
RT   gene.";
RL   DNA Cell Biol. 12:611-615(1993).
RN   [11]
RP   IDENTIFICATION IN A COMPLEX WITH PIK3C2A AND EGFR, IDENTIFICATION IN A
RP   COMPLEX WITH PIK3C2B AND EGFR, AND INTERACTION WITH PIK3C2B.
RX   PubMed=10805725; DOI=10.1128/MCB.20.11.3817-3830.2000;
RA   Arcaro A., Zvelebil M.J., Wallasch C., Ullrich A., Waterfield M.D.,
RA   Domin J.;
RT   "Class II phosphoinositide 3-kinases are downstream targets of
RT   activated polypeptide growth factor receptors.";
RL   Mol. Cell. Biol. 20:3817-3830(2000).
RN   [12]
RP   INTERACTION WITH MUC1.
RX   PubMed=12939402;
RA   Li Y., Yu W.-H., Ren J., Chen W., Huang L., Kharbanda S., Loda M.,
RA   Kufe D.;
RT   "Heregulin targets gamma-catenin to the nucleolus by a mechanism
RT   dependent on the DF3/MUC1 oncoprotein.";
RL   Mol. Cancer Res. 1:765-775(2003).
RN   [13]
RP   FUNCTION, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.
RX   PubMed=15380516; DOI=10.1016/j.ccr.2004.07.012;
RA   Wang S.C., Lien H.C., Xia W., Chen I.F., Lo H.W., Wang Z.,
RA   Ali-Seyed M., Lee D.F., Bartholomeusz G., Ou-Yang F., Giri D.K.,
RA   Hung M.C.;
RT   "Binding at and transactivation of the COX-2 promoter by nuclear
RT   tyrosine kinase receptor ErbB-2.";
RL   Cancer Cell 6:251-261(2004).
RN   [14]
RP   INTERACTION WITH PLXNB1.
RX   PubMed=15210733; DOI=10.1083/jcb.200312094;
RA   Swiercz J.M., Kuner R., Offermanns S.;
RT   "Plexin-B1/RhoGEF-mediated RhoA activation involves the receptor
RT   tyrosine kinase ErbB-2.";
RL   J. Cell Biol. 165:869-880(2004).
RN   [15]
RP   INTERACTION WITH MEMO.
RX   PubMed=15156151; DOI=10.1038/ncb1134;
RA   Marone R., Hess D., Dankort D., Muller W.J., Hynes N.E., Badache A.;
RT   "Memo mediates ErbB2-driven cell motility.";
RL   Nat. Cell Biol. 6:515-522(2004).
RN   [16]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-1248, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P.,
RA   Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in
RT   signaling networks.";
RL   Cell 127:635-648(2006).
RN   [17]
RP   FUNCTION, ALTERNATIVE INITIATION (ISOFORMS 2 AND 3), SUBCELLULAR
RP   LOCATION, AND MUTAGENESIS OF MET-611; MET-687; MET-706 AND MET-712.
RX   PubMed=16794579; DOI=10.1038/sj.emboj.7601191;
RA   Anido J., Scaltriti M., Bech Serra J.J., Santiago Josefat B.,
RA   Todo F.R., Baselga J., Arribas J.;
RT   "Biosynthesis of tumorigenic HER2 C-terminal fragments by alternative
RT   initiation of translation.";
RL   EMBO J. 25:3234-3244(2006).
RN   [18]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-735, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Lung carcinoma;
RX   PubMed=18083107; DOI=10.1016/j.cell.2007.11.025;
RA   Rikova K., Guo A., Zeng Q., Possemato A., Yu J., Haack H., Nardone J.,
RA   Lee K., Reeves C., Li Y., Hu Y., Tan Z., Stokes M., Sullivan L.,
RA   Mitchell J., Wetzel R., Macneill J., Ren J.M., Yuan J.,
RA   Bakalarski C.E., Villen J., Kornhauser J.M., Smith B., Li D., Zhou X.,
RA   Gygi S.P., Gu T.-L., Polakiewicz R.D., Rush J., Comb M.J.;
RT   "Global survey of phosphotyrosine signaling identifies oncogenic
RT   kinases in lung cancer.";
RL   Cell 131:1190-1203(2007).
RN   [19]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-1248, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Mammary epithelium;
RX   PubMed=17389395; DOI=10.1073/pnas.0608638104;
RA   Wolf-Yadlin A., Hautaniemi S., Lauffenburger D.A., White F.M.;
RT   "Multiple reaction monitoring for robust quantitative proteomic
RT   analysis of cellular signaling networks.";
RL   Proc. Natl. Acad. Sci. U.S.A. 104:5860-5865(2007).
RN   [20]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1054, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of
RT   the kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [21]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1054, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [22]
RP   X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) OF 654-662 IN COMPLEX WITH HLA
RP   AND BETA-2 MICROGLOBULIN.
RX   MEDLINE=20062861; PubMed=10593938; DOI=10.1074/jbc.274.51.36422;
RA   Kuhns J.J., Batalia M.A., Yan S., Collins E.J.;
RT   "Poor binding of a HER-2/neu epitope (GP2) to HLA-A2.1 is due to a
RT   lack of interactions with the center of the peptide.";
RL   J. Biol. Chem. 274:36422-36427(1999).
RN   [23]
RP   X-RAY CRYSTALLOGRAPHY (2.52 ANGSTROMS) OF 23-629 IN COMPLEX WITH FAB.
RX   MEDLINE=22497871; PubMed=12610629; DOI=10.1038/nature01392;
RA   Cho H.-S., Mason K., Ramyar K.X., Stanley A.M., Gabelli S.B.,
RA   Denney D.W. Jr., Leahy D.J.;
RT   "Structure of the extracellular region of HER2 alone and in complex
RT   with the Herceptin Fab.";
RL   Nature 421:756-760(2003).
RN   [24]
RP   VARIANTS VAL-654 AND VAL-655.
RX   MEDLINE=93194196; PubMed=8095488; DOI=10.1006/geno.1993.1081;
RA   Ehsani A., Low J., Wallace R.B., Wu A.M.;
RT   "Characterization of a new allele of the human ERBB2 gene by allele-
RT   specific competition hybridization.";
RL   Genomics 15:426-429(1993).
RN   [25]
RP   VARIANTS ADENOCARCINOMA OF LUNG PRO-755; ALA-TYR-VAL-MET-774 INS AND
RP   VAL-GLY-SER-779 INS, VARIANT GASTRIC CANCER SER-776, VARIANT OVARIAN
RP   CANCER SER-857, AND VARIANT GLIOBLASTOMA LYS-914.
RX   PubMed=15457249; DOI=10.1038/431525b;
RG   Cancer genome project and collaborative group;
RA   Stephens P., Hunter C., Bignell G., Edkins S., Davies H., Teague J.,
RA   Stevens C., O'Meara S., Smith R., Parker A., Barthorpe A., Blow M.,
RA   Brackenbury L., Butler A., Clarke O., Cole J., Dicks E., Dike A.,
RA   Drozd A., Edwards K., Forbes S., Foster R., Gray K., Greenman C.,
RA   Halliday K., Hills K., Kosmidou V., Lugg R., Menzies A., Perry J.,
RA   Petty R., Raine K., Ratford L., Shepherd R., Small A., Stephens Y.,
RA   Tofts C., Varian J., West S., Widaa S., Yates A., Brasseur F.,
RA   Cooper C.S., Flanagan A.M., Knowles M., Leung S.Y., Louis D.N.,
RA   Looijenga L.H., Malkowicz B., Pierotti M.A., Teh B.,
RA   Chenevix-Trench G., Weber B.L., Yuen S.T., Harris G., Goldstraw P.,
RA   Nicholson A.G., Futreal P.A., Wooster R., Stratton M.R.;
RT   "Lung cancer: intragenic ERBB2 kinase mutations in tumours.";
RL   Nature 431:525-526(2004).
RN   [26]
RP   VARIANTS [LARGE SCALE ANALYSIS] VAL-654; VAL-655; SER-768; SER-776;
RP   SER-857; ALA-1170 AND ASP-1216.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Essential component of a neuregulin-receptor complex,
CC       although neuregulins do not interact with it alone. GP30 is a
CC       potential ligand for this receptor. Binds to the 5'-TCAAATTC-3'
CC       sequence in the MT-CO2 promoter and activates its transcription.
CC   -!- CATALYTIC ACTIVITY: ATP + a [protein]-L-tyrosine = ADP + a
CC       [protein]-L-tyrosine phosphate.
CC   -!- ENZYME REGULATION: Not activated by EGF, TGF-alpha and
CC       amphiregulin.
CC   -!- SUBUNIT: Heterodimer with each of the other ERBB receptors
CC       (Potential). Interacts with PRKCABP and PLXNB1. Part of a complex
CC       with EGFR and either PIK3C2A or PIK3C2B. May interact with PIK3C2B
CC       when phosphorylated on Tyr-1196. Interacts with MEMO when
CC       phosphorylated on Tyr-1248. Interacts with MUC1. Stimulation by
CC       heregulin (HRG) in breast cancer cell lines induces binding of
CC       MUC1 with gamma-catenin.
CC   -!- INTERACTION:
CC       Self; NbExp=1; IntAct=EBI-641062, EBI-641062;
CC       P62157:CALM (xeno); NbExp=1; IntAct=EBI-641062, EBI-397403;
CC       P62161:Calm1 (xeno); NbExp=1; IntAct=EBI-641062, EBI-397530;
CC       P00533:EGFR; NbExp=2; IntAct=EBI-641062, EBI-297353;
CC       P21860:ERBB3; NbExp=7; IntAct=EBI-641062, EBI-720706;
CC       Q15303:ERBB4; NbExp=2; IntAct=EBI-641062, EBI-80371;
CC       Q02297:NRG1; NbExp=1; IntAct=EBI-641062, EBI-2460704;
CC       Q05209:PTPN12; NbExp=1; IntAct=EBI-641062, EBI-2266035;
CC       Q9Y2R2:PTPN22; NbExp=1; IntAct=EBI-641062, EBI-1211241;
CC       P26045:PTPN3; NbExp=1; IntAct=EBI-641062, EBI-1047946;
CC       P23467:PTPRB; NbExp=1; IntAct=EBI-641062, EBI-1265766;
CC       P08575:PTPRC; NbExp=1; IntAct=EBI-641062, EBI-1341;
CC       P23470:PTPRG; NbExp=1; IntAct=EBI-641062, EBI-2258115;
CC       Q12913:PTPRJ; NbExp=1; IntAct=EBI-641062, EBI-2264500;
CC       Q15262:PTPRK; NbExp=1; IntAct=EBI-641062, EBI-474052;
CC       Q16827:PTPRO; NbExp=1; IntAct=EBI-641062, EBI-723739;
CC       P23471:PTPRZ1; NbExp=1; IntAct=EBI-641062, EBI-2263175;
CC   -!- SUBCELLULAR LOCATION: Isoform 1: Cell membrane; Single-pass type I
CC       membrane protein. Cytoplasm, perinuclear region. Nucleus.
CC   -!- SUBCELLULAR LOCATION: Isoform 2: Cytoplasm. Nucleus.
CC   -!- SUBCELLULAR LOCATION: Isoform 3: Cytoplasm. Nucleus.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing, Alternative initiation; Named isoforms=4;
CC       Name=1; Synonyms=ERBB2, HER2;
CC         IsoId=P04626-1; Sequence=Displayed;
CC       Name=2; Synonyms=CTF-611;
CC         IsoId=P04626-2; Sequence=VSP_039249;
CC         Note=Produced by alternative initiation at Met-611 of isoform 1;
CC       Name=3; Synonyms=CTF-687;
CC         IsoId=P04626-3; Sequence=VSP_039250;
CC         Note=Produced by alternative initiation at Met-687 of isoform 1;
CC       Name=4;
CC         IsoId=P04626-4; Sequence=VSP_039248;
CC         Note=Produced by alternative splicing of isoform 1;
CC   -!- TISSUE SPECIFICITY: Expressed in a variety of tumor tissues
CC       including primary breast tumors and tumors from small bowel,
CC       esophagus, kidney and mouth.
CC   -!- PTM: Ligand-binding increases phosphorylation on tyrosine residues
CC       (By similarity).
CC   -!- POLYMORPHISM: There are fours alleles due to the variations in
CC       positions 654 and 655. Allele B1 (Ile-654/Ile-655) has a frequency
CC       of 0.782; allele B2 (Ile-654/Val-655) has a frequency of 0.206;
CC       allele B3 (Val-654/Val-655) has a frequency of 0.012.
CC   -!- DISEASE: Defects in ERBB2 are associated with gastric cancer
CC       [MIM:137215]; also known as hereditary familial diffuse gastric
CC       cancer (HDGC).
CC   -!- DISEASE: Defects in ERBB2 are involved in the development of
CC       glioma (GLM) [MIM:137800]. Gliomas are central nervous system
CC       neoplasms derived from glial cells and comprise astrocytomas,
CC       glioblastoma multiforme, oligodendrogliomas, and ependymomas.
CC   -!- DISEASE: Defects in ERBB2 are a cause of susceptibility to ovarian
CC       cancer (OC) [MIM:167000]. Ovarian cancer common malignancy
CC       originating from ovarian tissue. Although many histologic types of
CC       ovarian neoplasms have been described, epithelial ovarian
CC       carcinoma is the most common form. Ovarian cancers are often
CC       asymptomatic and the recognized signs and symptoms, even of late-
CC       stage disease, are vague. Consequently, most patients are
CC       diagnosed with advanced disease.
CC   -!- DISEASE: Defects in ERBB2 are associated with lung cancer
CC       [MIM:211980]; also called adenocarcinoma of lung.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. EGF receptor subfamily.
CC   -!- SIMILARITY: Contains 1 protein kinase domain.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/ERBB2ID162ch17q11.html";
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/erbb2/";
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=ERBB2 entry;
CC       URL="http://en.wikipedia.org/wiki/ERBB2";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M11767; AAA35808.1; -; Genomic_DNA.
DR   EMBL; M11761; AAA35808.1; JOINED; Genomic_DNA.
DR   EMBL; M11762; AAA35808.1; JOINED; Genomic_DNA.
DR   EMBL; M11763; AAA35808.1; JOINED; Genomic_DNA.
DR   EMBL; M11764; AAA35808.1; JOINED; Genomic_DNA.
DR   EMBL; M11765; AAA35808.1; JOINED; Genomic_DNA.
DR   EMBL; M11766; AAA35808.1; JOINED; Genomic_DNA.
DR   EMBL; X03363; CAA27060.1; -; mRNA.
DR   EMBL; M11730; AAA75493.1; -; mRNA.
DR   EMBL; M12036; AAA35978.1; -; Genomic_DNA.
DR   EMBL; AY208911; AAO18082.1; -; Genomic_DNA.
DR   EMBL; AK295195; BAG58195.1; -; mRNA.
DR   EMBL; CH471152; EAW60597.1; -; Genomic_DNA.
DR   EMBL; BC167147; AAI67147.1; -; mRNA.
DR   EMBL; M16792; AAA58637.1; -; Genomic_DNA.
DR   EMBL; M16789; AAA58637.1; JOINED; Genomic_DNA.
DR   EMBL; M16790; AAA58637.1; JOINED; Genomic_DNA.
DR   EMBL; M16791; AAA58637.1; JOINED; Genomic_DNA.
DR   EMBL; L29395; AAA35809.1; -; Genomic_DNA.
DR   EMBL; M95667; AAC37531.1; -; Genomic_DNA.
DR   IPI; IPI00300384; -.
DR   IPI; IPI00845478; -.
DR   IPI; IPI00941360; -.
DR   IPI; IPI00964086; -.
DR   PIR; A24571; A24571.
DR   RefSeq; NP_001005862.1; -.
DR   RefSeq; NP_004439.2; -.
DR   UniGene; Hs.446352; -.
DR   PDB; 1MFG; X-ray; 1.25 A; B=1247-1255.
DR   PDB; 1MFL; X-ray; 1.88 A; B=1247-1255.
DR   PDB; 1MW4; NMR; -; B=1135-1144.
DR   PDB; 1N8Z; X-ray; 2.52 A; C=23-629.
DR   PDB; 1OVC; Model; -; A=737-1031.
DR   PDB; 1QR1; X-ray; 2.40 A; C/F=654-662.
DR   PDB; 1S78; X-ray; 3.25 A; A/B=23-646.
DR   PDB; 2A91; X-ray; 2.50 A; A=22-530.
DR   PDB; 2JWA; NMR; -; A/B=641-684.
DR   PDB; 2KS1; NMR; -; A=641-684.
DR   PDB; 3BE1; X-ray; 2.90 A; A=23-646.
DR   PDB; 3H3B; X-ray; 2.45 A; A/B=22-214.
DR   PDB; 3MZW; X-ray; 2.90 A; A=23-646.
DR   PDB; 3N85; X-ray; 3.20 A; A=23-646.
DR   PDBsum; 1MFG; -.
DR   PDBsum; 1MFL; -.
DR   PDBsum; 1MW4; -.
DR   PDBsum; 1N8Z; -.
DR   PDBsum; 1OVC; -.
DR   PDBsum; 1QR1; -.
DR   PDBsum; 1S78; -.
DR   PDBsum; 2A91; -.
DR   PDBsum; 2JWA; -.
DR   PDBsum; 2KS1; -.
DR   PDBsum; 3BE1; -.
DR   PDBsum; 3H3B; -.
DR   PDBsum; 3MZW; -.
DR   PDBsum; 3N85; -.
DR   ProteinModelPortal; P04626; -.
DR   SMR; P04626; 677-729, 707-1025.
DR   DIP; DIP-8N; -.
DR   IntAct; P04626; 52.
DR   MINT; MINT-158636; -.
DR   STRING; P04626; -.
DR   PhosphoSite; P04626; -.
DR   PRIDE; P04626; -.
DR   Ensembl; ENST00000269571; ENSP00000269571; ENSG00000141736.
DR   GeneID; 2064; -.
DR   KEGG; hsa:2064; -.
DR   UCSC; uc002hso.1; human.
DR   CTD; 2064; -.
DR   GeneCards; GC17P037844; -.
DR   H-InvDB; HIX0039027; -.
DR   HGNC; HGNC:3430; ERBB2.
DR   HPA; CAB000043; -.
DR   HPA; CAB020416; -.
DR   HPA; HPA001383; -.
DR   MIM; 137215; phenotype.
DR   MIM; 137800; phenotype.
DR   MIM; 164870; gene.
DR   MIM; 167000; phenotype.
DR   MIM; 211980; phenotype.
DR   PharmGKB; PA27844; -.
DR   eggNOG; prNOG06030; -.
DR   HOGENOM; HBG445128; -.
DR   HOVERGEN; HBG000490; -.
DR   InParanoid; P04626; -.
DR   OMA; ACYPLCA; -.
DR   PhylomeDB; P04626; -.
DR   BRENDA; 2.7.10.1; 247.
DR   Pathway_Interaction_DB; a6b1_a6b4_integrin_pathway; a6b1 and a6b4 Integrin signaling.
DR   Reactome; REACT_18266; Axon guidance.
DR   DrugBank; DB01259; Lapatinib.
DR   DrugBank; DB01006; Letrozole.
DR   DrugBank; DB00072; Trastuzumab.
DR   NextBio; 8385; -.
DR   PMAP-CutDB; P04626; -.
DR   ArrayExpress; P04626; -.
DR   Bgee; P04626; -.
DR   CleanEx; HS_ERBB2; -.
DR   Genevestigator; P04626; -.
DR   GermOnline; ENSG00000141736; Homo sapiens.
DR   GO; GO:0016021; C:integral to membrane; NAS:UniProtKB.
DR   GO; GO:0005634; C:nucleus; IEA:UniProtKB-SubCell.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; IEA:UniProtKB-SubCell.
DR   GO; GO:0043235; C:receptor complex; IDA:BHF-UCL.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0003677; F:DNA binding; IEA:UniProtKB-KW.
DR   GO; GO:0005006; F:epidermal growth factor receptor activity; NAS:UniProtKB.
DR   GO; GO:0043125; F:ErbB-3 class receptor binding; TAS:ProtInc.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0008022; F:protein C-terminus binding; IPI:UniProtKB.
DR   GO; GO:0046982; F:protein heterodimerization activity; IDA:UniProtKB.
DR   GO; GO:0019903; F:protein phosphatase binding; IPI:UniProtKB.
DR   GO; GO:0004716; F:receptor signaling protein tyrosine kinase ...; TAS:ProtInc.
DR   GO; GO:0008283; P:cell proliferation; TAS:ProtInc.
DR   GO; GO:0007507; P:heart development; TAS:UniProtKB.
DR   GO; GO:0014065; P:phosphoinositide 3-kinase cascade; IDA:BHF-UCL.
DR   GO; GO:0048015; P:phosphoinositide-mediated signaling; NAS:UniProtKB.
DR   GO; GO:0045785; P:positive regulation of cell adhesion; IDA:BHF-UCL.
DR   GO; GO:0050679; P:positive regulation of epithelial cell prol...; IDA:UniProtKB.
DR   GO; GO:0043406; P:positive regulation of MAP kinase activity; IDA:UniProtKB.
DR   GO; GO:0046777; P:protein amino acid autophosphorylation; IDA:BHF-UCL.
DR   GO; GO:0045765; P:regulation of angiogenesis; NAS:UniProtKB.
DR   GO; GO:0045449; P:regulation of transcription; IEA:UniProtKB-KW.
DR   GO; GO:0006350; P:transcription; IEA:UniProtKB-KW.
DR   GO; GO:0042060; P:wound healing; IDA:BHF-UCL.
DR   InterPro; IPR021157; Cyt_c1_TM_anchor_C.
DR   InterPro; IPR000494; EGF_rcpt_L.
DR   InterPro; IPR006211; Furin-like_Cys-rich_dom.
DR   InterPro; IPR006212; Furin_repeat.
DR   InterPro; IPR009030; Growth_fac_rcpt.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR000719; Prot_kinase_cat_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR001245; Ser-Thr/Tyr-Pkinase.
DR   InterPro; IPR016245; Tyr_kinase_EGF/ERB/XmrK_rcpt.
DR   InterPro; IPR020760; Tyr_kinase_rcpt_ErbB-2.
DR   InterPro; IPR020635; Tyr_Pkinase_cat_dom.
DR   InterPro; IPR020685; Tyr_prot_kinase.
DR   InterPro; IPR008266; Tyr_prot_kinase_AS.
DR   Gene3D; G3DSA:1.20.5.100; Cyt_c1_TM_anchor_C; 1.
DR   PANTHER; PTHR23256:SF287; Tyr_kinase_rcpt_erbB-2; 1.
DR   PANTHER; PTHR23256; Tyr_prot_kinase; 1.
DR   Pfam; PF00757; Furin-like; 1.
DR   Pfam; PF07714; Pkinase_Tyr; 1.
DR   Pfam; PF01030; Recep_L_domain; 2.
DR   PIRSF; PIRSF000619; TyrPK_EGF-R; 1.
DR   PRINTS; PR00109; TYRKINASE.
DR   SMART; SM00261; FU; 3.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF57184; Grow_fac_recept; 2.
DR   SUPFAM; SSF56112; Kinase_like; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Activator; Alternative initiation; Alternative splicing;
KW   ATP-binding; Cell membrane; Complete proteome; Cytoplasm;
KW   Disulfide bond; DNA-binding; Glycoprotein; Kinase; Membrane;
KW   Nucleotide-binding; Nucleus; Phosphoprotein; Polymorphism; Receptor;
KW   Signal; Transcription; Transcription regulation; Transferase;
KW   Transmembrane; Transmembrane helix; Tyrosine-protein kinase.
FT   SIGNAL        1     22       Potential.
FT   CHAIN        23   1255       Receptor tyrosine-protein kinase erbB-2.
FT                                /FTId=PRO_0000016669.
FT   TOPO_DOM     23    652       Extracellular (Potential).
FT   TRANSMEM    653    675       Helical; (Potential).
FT   TOPO_DOM    676   1255       Cytoplasmic (Potential).
FT   DOMAIN      720    987       Protein kinase.
FT   NP_BIND     726    734       ATP (By similarity).
FT   REGION     1195   1197       Interaction with PIK3C2B (Probable).
FT   ACT_SITE    845    845       Proton acceptor (By similarity).
FT   BINDING     753    753       ATP (By similarity).
FT   MOD_RES     735    735       Phosphotyrosine.
FT   MOD_RES    1054   1054       Phosphoserine.
FT   MOD_RES    1139   1139       Phosphotyrosine; by autocatalysis (By
FT                                similarity).
FT   MOD_RES    1196   1196       Phosphotyrosine (Potential).
FT   MOD_RES    1248   1248       Phosphotyrosine; by autocatalysis (By
FT                                similarity).
FT   CARBOHYD     68     68       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    124    124       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    187    187       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    259    259       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    530    530       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    571    571       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    629    629       N-linked (GlcNAc...) (Potential).
FT   DISULFID    195    204       By similarity.
FT   DISULFID    199    212       By similarity.
FT   DISULFID    220    227       By similarity.
FT   DISULFID    224    235       By similarity.
FT   DISULFID    236    244       By similarity.
FT   DISULFID    240    252       By similarity.
FT   DISULFID    255    264       By similarity.
FT   DISULFID    268    295       By similarity.
FT   DISULFID    299    311       By similarity.
FT   DISULFID    315    331       By similarity.
FT   DISULFID    334    338       By similarity.
FT   DISULFID    511    520       By similarity.
FT   DISULFID    515    528       By similarity.
FT   DISULFID    531    540       By similarity.
FT   DISULFID    544    560       By similarity.
FT   DISULFID    563    576       By similarity.
FT   DISULFID    567    584       By similarity.
FT   DISULFID    587    596       By similarity.
FT   DISULFID    600    623       By similarity.
FT   DISULFID    626    634       By similarity.
FT   DISULFID    630    642       By similarity.
FT   VAR_SEQ       1    686       Missing (in isoform 3).
FT                                /FTId=VSP_039250.
FT   VAR_SEQ       1    610       Missing (in isoform 2).
FT                                /FTId=VSP_039249.
FT   VAR_SEQ       1     23       MELAALCRWGLLLALLPPGAAST -> MPRGSWKP (in
FT                                isoform 4).
FT                                /FTId=VSP_039248.
FT   VARIANT     452    452       W -> C (in dbSNP:rs4252633).
FT                                /FTId=VAR_016317.
FT   VARIANT     654    654       I -> V (in allele B3; dbSNP:rs1801201).
FT                                /FTId=VAR_004077.
FT   VARIANT     655    655       I -> V (in allele B2 and allele B3;
FT                                dbSNP:rs1136201).
FT                                /FTId=VAR_004078.
FT   VARIANT     755    755       L -> P (in adenocarcinoma of lung;
FT                                somatic mutation).
FT                                /FTId=VAR_055432.
FT   VARIANT     768    768       L -> S (in dbSNP:rs56366519).
FT                                /FTId=VAR_042097.
FT   VARIANT     774    774       M -> MAYVM (in adenocarcinoma of lung;
FT                                somatic mutationa).
FT                                /FTId=VAR_055433.
FT   VARIANT     776    776       G -> S (in a gastric adenocarcinoma
FT                                sample; somatic mutation;
FT                                dbSNP:rs28933369).
FT                                /FTId=VAR_042098.
FT   VARIANT     779    779       S -> SVGS (in adenocarcinoma of lung;
FT                                somatic mutation).
FT                                /FTId=VAR_055434.
FT   VARIANT     857    857       N -> S (in ovarian cancer; somatic
FT                                mutation; dbSNP:rs28933370).
FT                                /FTId=VAR_042099.
FT   VARIANT     914    914       E -> K (in glioblastoma; somatic
FT                                mutation; dbSNP:rs28933368).
FT                                /FTId=VAR_055435.
FT   VARIANT    1170   1170       P -> A (in dbSNP:rs1058808 and
FT                                dbSNP:rs61552325).
FT                                /FTId=VAR_016318.
FT   VARIANT    1216   1216       A -> D (in dbSNP:rs55943169).
FT                                /FTId=VAR_042100.
FT   MUTAGEN     611    611       M->A: Prevents synthesis of isoform 2.
FT   MUTAGEN     687    687       M->A: Prevents synthesis of isoform 3.
FT   MUTAGEN     706    706       M->A: No effect on isoform production.
FT   MUTAGEN     712    712       M->A: No effect on isoform production.
FT   STRAND       25     27
FT   HELIX        39     50
FT   STRAND       55     64
FT   HELIX        72     74
FT   STRAND       79     82
FT   STRAND       84     88
FT   TURN        109    111
FT   STRAND      112    117
FT   STRAND      152    157
FT   TURN        164    166
FT   HELIX       169    172
FT   HELIX       175    177
FT   STRAND      182    184
FT   STRAND      199    202
FT   STRAND      204    208
FT   STRAND      217    219
FT   STRAND      221    223
FT   STRAND      227    231
FT   HELIX       232    234
FT   STRAND      240    242
FT   STRAND      244    248
FT   STRAND      251    260
FT   STRAND      263    267
FT   STRAND      271    274
FT   TURN        276    278
FT   STRAND      281    283
FT   STRAND      289    291
FT   STRAND      294    298
FT   STRAND      303    305
FT   STRAND      309    314
FT   STRAND      319    323
FT   STRAND      329    333
FT   STRAND      335    337
FT   HELIX       348    350
FT   TURN        358    360
FT   HELIX       361    364
FT   STRAND      368    376
FT   HELIX       378    380
FT   HELIX       396    402
FT   STRAND      405    408
FT   STRAND      410    413
FT   HELIX       423    425
FT   TURN        438    440
FT   STRAND      441    447
FT   STRAND      463    469
FT   HELIX       482    485
FT   STRAND      493    498
FT   HELIX       501    506
FT   HELIX       516    518
FT   STRAND      520    524
FT   STRAND      528    536
FT   STRAND      539    542
FT   STRAND      545    551
FT   STRAND      553    556
FT   STRAND      559    562
FT   STRAND      571    573
FT   STRAND      575    580
FT   STRAND      583    592
FT   STRAND      595    599
FT   STRAND      615    617
FT   STRAND      621    625
FT   HELIX       651    678
SQ   SEQUENCE   1255 AA;  137910 MW;  39E9DFDA04DCF962 CRC64;
     MELAALCRWG LLLALLPPGA ASTQVCTGTD MKLRLPASPE THLDMLRHLY QGCQVVQGNL
     ELTYLPTNAS LSFLQDIQEV QGYVLIAHNQ VRQVPLQRLR IVRGTQLFED NYALAVLDNG
     DPLNNTTPVT GASPGGLREL QLRSLTEILK GGVLIQRNPQ LCYQDTILWK DIFHKNNQLA
     LTLIDTNRSR ACHPCSPMCK GSRCWGESSE DCQSLTRTVC AGGCARCKGP LPTDCCHEQC
     AAGCTGPKHS DCLACLHFNH SGICELHCPA LVTYNTDTFE SMPNPEGRYT FGASCVTACP
     YNYLSTDVGS CTLVCPLHNQ EVTAEDGTQR CEKCSKPCAR VCYGLGMEHL REVRAVTSAN
     IQEFAGCKKI FGSLAFLPES FDGDPASNTA PLQPEQLQVF ETLEEITGYL YISAWPDSLP
     DLSVFQNLQV IRGRILHNGA YSLTLQGLGI SWLGLRSLRE LGSGLALIHH NTHLCFVHTV
     PWDQLFRNPH QALLHTANRP EDECVGEGLA CHQLCARGHC WGPGPTQCVN CSQFLRGQEC
     VEECRVLQGL PREYVNARHC LPCHPECQPQ NGSVTCFGPE ADQCVACAHY KDPPFCVARC
     PSGVKPDLSY MPIWKFPDEE GACQPCPINC THSCVDLDDK GCPAEQRASP LTSIISAVVG
     ILLVVVLGVV FGILIKRRQQ KIRKYTMRRL LQETELVEPL TPSGAMPNQA QMRILKETEL
     RKVKVLGSGA FGTVYKGIWI PDGENVKIPV AIKVLRENTS PKANKEILDE AYVMAGVGSP
     YVSRLLGICL TSTVQLVTQL MPYGCLLDHV RENRGRLGSQ DLLNWCMQIA KGMSYLEDVR
     LVHRDLAARN VLVKSPNHVK ITDFGLARLL DIDETEYHAD GGKVPIKWMA LESILRRRFT
     HQSDVWSYGV TVWELMTFGA KPYDGIPARE IPDLLEKGER LPQPPICTID VYMIMVKCWM
     IDSECRPRFR ELVSEFSRMA RDPQRFVVIQ NEDLGPASPL DSTFYRSLLE DDDMGDLVDA
     EEYLVPQQGF FCPDPAPGAG GMVHHRHRSS STRSGGGDLT LGLEPSEEEA PRSPLAPSEG
     AGSDVFDGDL GMGAAKGLQS LPTHDPSPLQ RYSEDPTVPL PSETDGYVAP LTCSPQPEYV
     NQPDVRPQPP SPREGPLPAA RPAGATLERP KTLSPGKNGV VKDVFAFGGA VENPEYLTPQ
     GGAAPQPHPP PAFSPAFDNL YYWDQDPPER GAPPSTFKGT PTAENPEYLG LDVPV
//
